Peer-Reviewed Publications

• Joshi AS*, Tomaz da Silva M*, Roy A* et al. The IRE1α/XBP1/Myomaker axis drives myoblast fusion in adult skeletal muscle bioRxiv 2023.09.26.559625; doi: https://doi.org/10.1101/2023.09.26.559625.
  *Equal contribution first author
• Tomaz da Silva M, Joshi AS, Castillo MB, Koike TE, Roy A, Gunaratne PH, Kumar A (2023). Fn14 promotes myoblast fusion during regenerative myogenesis. Life Science Alliance manuscript in press.
• Roy A*, Koike E T, Joshi S A, et al. (2023). Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model. JCI Insight 2023;8(10):e164768.
  *Co-corresponding author.
• Roy A, Koike E T, Joshi S A, et al. (2023). Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model. JCI Insight Apr 18;e164768.
• Roy A, Narkar VA, Kumar A (2023). Emerging role of TAK1 in the regulation of skeletal muscle mass. BioEssays, 45, e2300003.
• Sopariwala, DH, Rios, AS, Pei, G, Roy A et al. (2022). Innately expressed estrogen-related receptors in the skeletal muscle are indispensable for exercise fitness. FASEB Journal. 2023; 37:e22727.
• Tomaz da Silva M, Joshi S A, Koike E T, Roy A, et al. (2022). Targeted ablation of Fn14 receptor improves exercise capacity and inhibits neurogenic muscle atrophy. FASEB Journal. 12, 36.
• Roy A, Kumar A. (2022). Supraphysiological activation of TAK1 promotes skeletal muscle growth and mitigates neurogenic atrophy. Nature Communications 13, 2201.
• Roy A, Tomaz da Silva M, Bhat R, Bohnert KR, Iwawaki T, and Kumar A. (2021). The IRE1/XBP1 signaling axis promotes skeletal muscle regeneration through a cell non-autonomous mechanism. eLife.10:e73215.
• Parveen A, Bohnert KR, Tomaz da Silva M, Wen Y, Bhat R, Roy A, Kumar A. (2021). MyD88-mediated signaling intercedes in neurogenic muscle atrophy through multiple mechanisms. FASEB Journal. Aug;35(8):e21821.
• Parveen A, Wen Y, Roy A, Kumar A. (2021). Therapeutic Targeting of Pten in Duchenne Muscular Dystrophy Molecular Therapy: the Journal of the American Society of Gene Therapy, 29(1):8-9
• Roy A, Sharma AK, Nellore K, Narkar VA, Kumar A. (2020). TAK1 preserves skeletal muscle mass and mitochondrial function through redox homeostasis. FASEB BioAdvances. 2 (9), 538-553.
• Roy A, Kumar A. (2019). ER stress and unfolded protein response in cancer cachexia. Cancers (Basel)11 (12), 1929.
• Bohnert KR, Goli P, Roy A, Sharma AK, Xiong G, Gallot YS, Kumar A. (2019). TLR/MyD88/XBP1 signaling axis mediates skeletal musclewastingduringcancercachexia.MolecularCellBiology.39:e00184-19.
• Roy A, Sarker S, Upadhyay P, Pal A, Adhikary A, Jana K, Ray M. (2018). Methylglyoxal at metronomic doses sensitizes breast cancer cells to doxorubicin and cisplatin causing synergistic induction of programmed cell death and inhibition of stemness. Biochemical Pharmacology.156, 322–339.
• Roy A, Ahir M, Bhattacharya S, et al. (2017). Induction of Mitochondrial Apoptotic Pathway in Triple Negative Breast Carcinoma Cells by Methylglyoxal via Generation of Reactive Oxygen Species. Molecular Carcinogenesis;56(9):2086-2103. doi:10.1002/mc.22665.

Selected Presentations at Conferences

• Roy A, Jana K, Ray M. Anticancer Activity of Methylglyoxal on Triple Negative Breast Carcinoma is primarily mediated by Reactive Oxygen Species – Poster presentation at the 19th International Conference on Oxidative Stress Reduction, Redox Homeostasis and Antioxidants, Paris Redox 2017 organized by The Sorbonne University Pierre and Marie Curie, Paris, France.
• Roy A, Ray M. Preclinical Studies of Nanofabricated Methylglyoxal; Combination with Conventional Chemotherapeutic drugs and Effects on Cancer Stem Cells – Oral presentation at the 1st International Conference on Clinical Trial & Innovative Therapeutics held on July 2017 organized by SATA, SA and Larkin University, USA at Cape Town, South Africa.
• Roy A, Ghosh A, Ray M. Methylglyoxal Induces Mitochondria Dependent Apoptosis in Sarcoma and Carcinoma – Poster presentation at the EMBO Workshop on Mitochondria, Apoptosis and Cancer 2017 organized by the Joseph Stephan Institute, Ljubljana, Slovenia at Bled, Slovenia.
• Roy A, Kumar A. TAK1 promotes skeletal muscle growth and inhibits neurogenic muscle atrophy. Oral presentation at the PPS Research Symposium 2021, College of Pharmacy University of Houston. USA.
• Roy A, Kumar A. TAK1 is a positive regulator of skeletal muscle mass. Oral presentation at the PPS Research Symposium 2022, College of Pharmacy University of Houston. USA.
• Roy A, Koike TE. Joshi AS et. al. Temporal regulation of TAK1 mitigates disease progression in a DMD mouse model. Poster presentation at the Advances in Skeletal Muscle Biology Conference, Myology Institute, University of Florida, USA.